Download PDF
J Reconstr Microsurg 2006; 22(1): 059-066
DOI: 10.1055/s-2006-931909
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Sarpogrelate Hydrochloride, an Antagonist of 5-Hydroxytryptamine Receptor, Improves Skin Flap Survival and Suppresses Thrombus Formation in Injured Microvessels of Rabbits

Maki Toda Takase1 , Ichiro Hashimoto1 , Hideki Nakanishi1 , Yutaka Nakaya2 , Hiroshi Harada3 , Hiromichi Sedo1 , Ikuno Kanda1
  • 1Department of Plastic and Aesthetic Surgery, School of Medicine, University of Tokushima, Tokushima, Japan
  • 2Department of Nutrition, School of Medicine, University of Tokushima, Tokushima, Japan
  • 3Department of Plastic and Reconstructive Surgery, Tokushima Red Cross Hospital, Tokushima, Japan
Further Information

Publication History

Accepted: September 20, 2005

Publication Date:
19 January 2006 (online)

    Permissions and Reprints

ABSTRACT

The authors carried out two studies to examine the effects of the 5-hydroxytryptamine receptor antagonist, sarpogrelate hydrochloride (SH), on flap necrosis. The first study measured survival rates and included histologic examination of random-pattern skin flaps in rabbits. The second study assessed the time to complete obstruction of blood flow with the artificial thrombus formation method, and the time for leukocytes to adhere to the endothelium of microvessels in a rabbit-ear chamber. The treatment groups were injected with SH. The survival rates of skin flaps in the SH-treated group were increased significantly. Histologic examination of vessels in the control group revealed that vessels in the deep dermis were obstructed completely by thrombi, whereas such vessels were not obstructed in the SH-treated group. Thrombus formation time and leukocyte adhesion time in the SH-treated group were prolonged and decreased, respectively. Thus, SH maintained flap circulation and promoted flap survival by preventing thrombus formation.

KEYWORDS

5-hydroxytryptamine receptor antagonist - flap necrosis - rabbit ear chamber - thrombus formation

REFERENCES

  • 1 Galla T J, Saetzler R K, Hammersen F, Messmer K. Increase in skin-flap survival by the vasoactive drug buflomedil.  Plast Reconstr Surg. 1991;  87 130-136
    PubMedGoogle Scholar
  • 2 Alexandrou K, Hata Y, Matsuka K, Matsuda H. Effect of beraprost sodium (Procylin), a stable prostaglandin I2 analogue, on a dorsal skin flap model in rats.  Scand J Plast Reconstr Surg Hand Surg. 1996;  30 17-20
    CrossrefPubMedGoogle Scholar
  • 3 Pang C Y, Chiu C, Zhong A, Xu N. Pharmacologic intervention of skin vasospasm and ischemic necrosis in pigs.  J Cardiovasc Pharmacol. 1993;  21 163-171
    PubMedGoogle Scholar
  • 4 Hodges P L. Surgical flaps.  Sel Read Plast Surg. 1992;  7 1-31
    PubMedGoogle Scholar
  • 5 Suzuki S, Yoshioka N, Isshiki N, Hamanaka H, Miyachi Y. Involvement of reactive oxygen species in post-ischaemic flap necrosis and its prevention by antioxidants.  Br J Plast Surg. 1991;  44 130-134
    CrossrefPubMedGoogle Scholar
  • 6 Rapport M M, Green A A, Page I H. Partial purification of the vasoconstrictor in beef serum.  J Biol Chem. 1948;  174 735-741
    PubMedGoogle Scholar
  • 7 Rapport M M, Green A A, Page I H. Serum vasoconstrictor (serotonin). IV. Isolation and characterization.  J Biol Chem. 1948;  176 1243-1251
    PubMedGoogle Scholar
  • 8 Zhong A, Pang C Y, Sheffield W D, Morris S F, Forrest C R. Augmentation of acute random pattern skin flap viability in the pig.  J Surg Res. 1992;  52 177-183
    PubMedGoogle Scholar
  • 9 Singh B N, Nademanee K, Symoens J, Janssens M. Ketanserin and QTc prolongation.  Eur Heart J. 1987;  8 667-668
    PubMedGoogle Scholar
  • 10 Prevention of Atherosclerotic Complications with Ketanserin Trial Group . Prevention of atherosclerotic complications: controlled trial of ketanserin.  Br Med J. 1989;  298 424-430
    PubMedGoogle Scholar
  • 11 Mikawa K, Akamatsu H, Nishina K et al.. The effects of sarpogrelate on superoxide production by human neutrophils.  Reg Anesth Pain Med. 2000;  25 181-186
    CrossrefPubMedGoogle Scholar
  • 12 Hara H, Kitajima A, Shimada H, Tamao Y. Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models.  Thromb Haemost. 1991;  66 484-488
    PubMedGoogle Scholar
  • 13 Hashimoto I, Nakanishi H, Shono Y, Tanaka S. The effects of desferrioxamine on thrombus formation in injured microvessels of the rabbit ear.  J Med Invest. 1999;  46 200-204
    PubMedGoogle Scholar
  • 14 Hashimoto I, Nakanishi H, Shono Y, Yamano M, Toda M. The features of thrombus in a microvessel injury model and the antithrombotic efficacy of heparin, urokinase, and prostaglandin E1 .  Plast Reconstr Surg. 2003;  111 2307-2314
    CrossrefPubMedGoogle Scholar
  • 15 Ono I, Ohura T, Murazumi M, Sakamura R, Chiba S. A study on the effectiveness of a thromboxane synthetase inhibitor (OKY-046) in increasing the survival length of skin flaps.  Plast Reconstr Surg. 1990;  86 1164-1173
    PubMedGoogle Scholar
  • 16 Hoyer D, Clarke D E, Fozard J R et al.. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).  Pharmacol Rev. 1994;  46 157-203
    PubMedGoogle Scholar
  • 17 Sato M, Ohshima N. Platelet thrombus induced in vivo by filtered light and fluorescent dye in mesenteric microvessels of the rat.  Thromb Res. 1984;  35 319-334
    CrossrefPubMedGoogle Scholar
  • 18 Sato M, Ohshima N. Hemodynamics at stenoses formed by growing platelet thrombi in mesenteric microvasculature of rat.  Microvasc Res. 1986;  31 66-76
    CrossrefPubMedGoogle Scholar

Maki Toda TakaseM.D. 

Department of Plastic and Aesthetic Surgery, School of Medicine, University of Tokushima, Kuramoto-2, Tokushima 770-8503, Japan

      >